Allogeneic blood lymphocytes activated with recombinant interleukin-2 (rIL-2)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Allogeneic blood lymphocytes activated with recombinant interleukin-2 (rIL-2), covering 2007-03-14 to 2007-03-14. Get the full timeline:
Most recent: Clinical Trial Update: Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors [Phase 2]